




RealRate

PHARMACEUTICAL 2016

Kiora Pharmaceuticals INC
Rank 203 of 295



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Kiora Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kiora Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 64% points. The greatest weakness of Kiora Pharmaceuticals INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 211%, being 52% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	9,449
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,421
Liabilities, Non-Current	0
Other Assets	59
Other Compr. Net Income	119
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,710
Other Revenues	0
Property and Equipment	0
Research and Development	2,717
Selling, General and Administrative Expense	3,960

Output Variable	Value in 1000 USD
Assets	9,508
Liabilities	3,421
Expenses	6,678
Revenues	0
Stockholders Equity	6,087
Net Income	-8,388
Comprehensive Net Income	-8,328
BaseVar	10,718
ECR before Limited Liability	76%
Economic Capital Ratio	211%